Death toll rises to 36 following an explosion and fire at a southern India pharmaceutical factory
The fire department recovered the charred bodies of 34 workers from the accident site in an industrial area about 50 kilometers (31 miles) from the state capital Hyderabad, the state's fire services director G.V. Narayana Rao told The Associated Press.
Two other workers succumbed to burns and were pronounced dead in hospital, Rao said, adding that debris of the gutted pharmaceutical unit of Sigachi Industries was still being removed to find out if any more workers were trapped.
Nearly three dozen injured workers were admitted to hospitals, he said.
"The whole structure of the factory has collapsed. Fire has been doused, and we hope to finish removing the debris in the next few hours," Rao said.
The explosion and subsequent fire was reported on Monday in the factory's spray dryer unit, which is used to process raw material into fine powder for making drugs, Rao said.
The state's Health Minister Damodar Raja Narasimha said there were 108 workers inside the factory at the time of the explosion.
"As bodies were badly burnt and mutilated, a special medical team has been deployed to conduct DNA tests", said Narasimha, adding the state government has set up a panel to investigate the cause of the incident.
Witnesses said they heard the explosion from a couple of kilometers away from the site.
India is home to some of the world's top pharmaceutical companies, playing a pivotal role in the global supply of generic medicines and vaccines. The country's robust manufacturing and cost-effective production have made it a hub for pharma giants.
Industrial accidents, particularly involving chemical reactors, aren't uncommon in such factories, underlining the need for authorities to implement stringent safety protocols and regulatory oversight in a sector critical to public health.
Sigachi Industries Limited is an Indian company dealing with active pharmaceutical ingredients, intermediates and vitamin-mineral blends, according to the company's website. It has five manufacturing facilities across India and subsidiaries in the U.S and the United Arab Emirates.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Mainichi
16 hours ago
- The Mainichi
Foreign medical residents fill critical positions at US hospitals, but are running into visa issues
(AP)-- Some hospitals in the U.S. are without essential staff because international doctors who were set to start their medical training this week were delayed by the Trump administration's travel and visa restrictions. It's unclear exactly how many foreign medical residents were unable to start their assignments, but six medical residents interviewed by The Associated Press say they've undergone years of training and work only to be stopped at the finish line by what is usually a procedural step. "I don't want to give up," said a permanent Canadian resident who matched to the University of Pittsburgh Medical Center Harrisburg but had her visa denied because she is a citizen of Afghanistan. She requested to remain anonymous for fear of reprisal. "But the situation also seems so helpless." Initially, the medical community was worried that hundreds of positions -- many in hospitals in low-income or rural areas of the U.S. -- could be affected. The pause on interviews for J-1 visas for approved work or study-related programs was lifted in mid-June. The national nonprofit that facilitates the residency match process said the visa situation is resolving, but it will take weeks to know with confidence how many medical residents have had the start of their careers derailed because they got their visa too late or were blocked by President Donald Trump's travel ban on 12 countries, according to people who coordinate the residents' training. Four foreign medical residents told the AP that U.S. embassies have been slow to open up interview slots -- and some have not opened any. "You lose out on the time you could have used to treat patients," said one resident from Pakistan, who matched to an internal medicine program in Massachusetts and requested to remain anonymous for fear of reprisal. Thousands of foreign medical residents fill gaps in U.S. hospitals The U.S. is projected to face a physician shortage in the next 11 years, per the Association of American Medical Colleges, and foreign medical residents fill critical gaps in the health care system. More than 6,600 foreign-born international medical residents matched into U.S. programs in 2025 -- the highest on record -- and another 300 filled positions that were vacant after the match process was complete. Not all of those residents were affected by visa issues or the travel ban on foreign nationals from countries including Afghanistan, Haiti and Sudan. International medical graduates often take jobs in places where U.S. medical trainees tend not to go, said Donna Lamb, president of the National Resident Matching Program. "It's not just that they're coming in and they want to work in big, flashy centers on the coast," Lamb said. "They're truly providing health care for all of America." Foreign medical residents work in specialties that U.S. applicants aren't as eager to apply to. For example, international candidates make up almost 40% of residents in internal medicine, which specializes in the prevention and treatment of chronic conditions like diabetes and heart disease. "The residents are the backbone of the entire hospital," said Dr. Zaid Alrashid from Brookdale University Hospital and Medical Center in New York, which has medical residents from almost every continent. Most received their visas prior to the pause but a few were caught up in delays. Two residents from India who spoke on condition of anonymity have not been able to get an appointment at any U.S. embassies there despite the J-1 visa pause being lifted. Another resident from Egypt just secured a visa appointment for mid-August but is worried her program may not be willing to wait for her. She's already paid her security deposit for an apartment in Texas to live during her residency. "I don't know when this situation will be resolved," said the resident, who spoke on condition of anonymity, adding she hasn't been eating or sleeping well. Hospitals waiting for residents to arrive In California, leaders at two graduate medical education programs said they have a small number of residents caught up in J-1 visa delays. Both spoke on condition of anonymity due to concerns for the doctors who are still trying to get visas. A residency leader at one large health care system said two doctors in its 150-resident program are delayed, adding they could start late or defer to next year. A 135-person program at a California public health system told the AP that one resident has yet to arrive, though he was finally scheduled for a visa interview. "We are not going to breathe easy until he's here in our hospital," the second leader said. As of Wednesday, Lamb's matching program had received fewer than 20 requests to defer or cancel residency contracts. Worried about losing their spots if they defer, many foreign medical residents may keep trying to get to the U.S. and start their residencies late, said Dr. Sabesan Karuppiah, a past member of the American Medical Association's International Medical Graduates Governing Council and former director of a large residency program. Some hospitals may struggle at this point to replace the residents who don't make it, leaving fewer people to care for the same number of patients, said Kimberly Pierce Burke, executive director of the Alliance of Independent Academic Medical Centers. Foreign medical trainees who've made it into the U.S. remain on edge about their situations, Karuppiah said. "I can tell you the word on the street is: 'Do not leave the country,'" he said, adding that people are missing out on important events, seeing sick parents or even getting married. "Everybody's scared to just leave, not knowing what's going to happen."
Yomiuri Shimbun
3 days ago
- Yomiuri Shimbun
Explosion at Pharmaceutical Factory in South India Kills at Least 36
At least 36 people were killed and dozens more injured in an explosion at a pharmaceutical factory in the southern Indian state of Telangana, state authorities said. The death toll is expected to rise as rescue workers continue to search the site following Monday's blast. Dozens of people remain missing. The blast occurred around 9 a.m. local time Monday at a plant in Pashamylaram, some 30 miles west of Hyderabad, the state capital. According to reports by local outlets, the explosion flattened a four-story building and threw workers hundreds of feet. More than 140 people were on-site when the explosion occurred, officials told reporters. The bodies were 'badly burnt and mutilated,' Telangana Health Minister Damodar Raja Narasimha told the Associated Press, and DNA tests were necessary to identify remains. The cause of the explosion is under investigation. Photos from the scene show rubble heaped stories high. The Telangana state government and Sigachi Industries, the operator of the factory, are set to pay 10 million rupees, around $117,000, to family members of each of the deceased, Telangana Chief Minister Revanth Reddy said in televised remarks. Injured workers are also set to receive compensation. Indian Prime Minister Narendra Modi expressed his condolences on X and pledged an additional 200,000 rupees, around $2,300, to the families of the deceased. The Pashamylaram plant is one of Sigachi's three manufacturing units, according to company documentation. India is the third-largest pharmaceutical industry in the world by volume and the leading supplier of generic medicines and vaccines. Labor and human rights watchdogs have warned of inadequate safety measures and lax oversight in some Indian factories. In a 2020 report on human rights in India, the U.S. State Department found that health and safety inspection capacity was insufficient and enforcement often poor. Global union federation InustriALL said that some 235 workers died across 116 industrial accidents in India between May 2020 and June 2021, according to media accounts and reports by the group's affiliates. The Pashamylaram blast came after a series of industrial accidents in the country. An August explosion at a chemical plant in Atchutapuram, in the neighboring state of Andhra Pradesh, left 17 workers dead. In May 2024, two unrelated explosions at chemical factories in Mumbai and the eastern state of Chhattisgarh killed at least 11, according to news items published by Britain's Royal Society of Chemistry. The 1984 Bhopal disaster, the world's worst industrial accident, occurred when a leak at a pesticide plant exposed hundreds of thousands of people in the central Indian city of Bhopal to a highly toxic gas and left a death toll in the thousands.
The Mainichi
4 days ago
- The Mainichi
Death toll rises to 36 following an explosion and fire at a southern India pharmaceutical factory
HYDERABAD, India (AP) -- The death toll from Monday's massive explosion and fire at a pharmaceutical factory in India's southern state of Telangana has risen to at least 36 while about three dozen were left injured, authorities said Tuesday. The fire department recovered the charred bodies of 34 workers from the accident site in an industrial area about 50 kilometers (31 miles) from the state capital Hyderabad, the state's fire services director G.V. Narayana Rao told The Associated Press. Two other workers succumbed to burns and were pronounced dead in hospital, Rao said, adding that debris of the gutted pharmaceutical unit of Sigachi Industries was still being removed to find out if any more workers were trapped. Nearly three dozen injured workers were admitted to hospitals, he said. "The whole structure of the factory has collapsed. Fire has been doused, and we hope to finish removing the debris in the next few hours," Rao said. The explosion and subsequent fire was reported on Monday in the factory's spray dryer unit, which is used to process raw material into fine powder for making drugs, Rao said. The state's Health Minister Damodar Raja Narasimha said there were 108 workers inside the factory at the time of the explosion. "As bodies were badly burnt and mutilated, a special medical team has been deployed to conduct DNA tests", said Narasimha, adding the state government has set up a panel to investigate the cause of the incident. Witnesses said they heard the explosion from a couple of kilometers away from the site. India is home to some of the world's top pharmaceutical companies, playing a pivotal role in the global supply of generic medicines and vaccines. The country's robust manufacturing and cost-effective production have made it a hub for pharma giants. Industrial accidents, particularly involving chemical reactors, aren't uncommon in such factories, underlining the need for authorities to implement stringent safety protocols and regulatory oversight in a sector critical to public health. Sigachi Industries Limited is an Indian company dealing with active pharmaceutical ingredients, intermediates and vitamin-mineral blends, according to the company's website. It has five manufacturing facilities across India and subsidiaries in the U.S and the United Arab Emirates.
